Radiation at Montebello Islands still 4,500 times higher than WA coast after nuclear blasts
Cam McGurk's stories of one of Australia's most heavily irradiated areas come drenched in warm Pilbara sunshine.
"I actually spent my honeymoon at the Montebello Islands," Mr McGurk, a longtime member of the Ashburton Anglers fishing club, said.
"It was the middle of COVID, so all the travel restrictions were in place … that was the one island holiday where I could take my beautiful wife.
The fondness locals like Mr McGurk feel for the islands, about 1,300 kilometres north of Perth, could soon be given fresh pause.
According to a landmark study published today, the archipelago's atomic contamination runs astonishingly deep.
The Montebello Islands were the site of three British atmospheric nuclear weapons tests between 1952 and 1956.
Two of the around 174 spits of sandy earth are still subject to hour-long visitation limits.
Since 2019, a team of researchers from Edith Cowan University has sought to measure precisely how much plutonium remains in the islands' marine sediment.
Their findings have now revealed levels reaching up to 4,500 times higher than the rest of the WA coast.
Scientists spent eight days on the Montebello Islands, diving to gather surface sediment from the ocean floor.
Samples were sent to the Australian Radiation Protection and Nuclear Safety Agency, the chief regulator for historic nuclear testing sites.
"We're able to essentially create a map with the over 66 locations that we took samples of sediment from," lead researcher and PhD candidate Madison Williams-Hoffman said.
Ms Williams-Hoffman said two "mechanisms" were spreading radiation through the islands over the past 70 years.
"The first one is the plume trajectories … like the mushroom clouds that you conjure in your mind when you think of nuclear detonations," she said.
"Those travelled with the wind direction at the time of the detonations."
Second, decades of tides and severe weather dispersed residual plutonium in unexpected ways.
"There are two cyclones a year that directly impact that part of WA, and so sediment is being tossed up and around, and things [are] moving," Ms Williams-Hoffman said.
She said concentrations in the islands' north were "comparable" to other places touched by nuclear testing, including French Polynesia and the Marshall Islands.
Any degree of similarity was remarkable because the Marshall Islands suffered a cumulative nuclear impact 700 times greater than the Montebello Islands.
"It makes us question what's different between the two sites," Ms Williams-Hoffman said.
The legacy of British nuclear testing in Australia is fraught with displacement and disease.
Following three major tests conducted on the Montebello Islands, two more nuclear devices were detonated at Emu Fields and another seven at Maralinga in South Australia.
Ray Kaye, former president of the Australian Ex-Services Atomic Survivors Association, said it was crucial the impacts of radiation were recorded.
The 85-year-old, who later contracted leukaemia, was awarded a medal by the British government for his involvement in the SA nuclear tests.
Mr Kaye reminisced on a 2016 trip with his fellow veterans to the Montebello Islands, marking the 60th anniversary of the blasts.
WA Parks and Wildlife marine program coordinator Tim Hunt said managing radiation on the Montebello Islands was an "interesting" part of the job.
"When I came into this role almost nine years ago, I never thought I'd have to get my physics hat on and learn about radiation," Mr Hunt said.
He noted that exposure to marine sediment was far less concerning to authorities.
"I'm not an expert, but people aren't going down and putting their head in the sand at 10 or 16 metres," he said.
"Our current understanding is that the measures we have in place are sufficient to mitigate that risk."
Visitors to Trimouille and Alpha Islands, where the three tests took place, are advised to restrict their time to no more than one hour per day, and not to disturb the soil or handle any relics.
Ms Williams-Hoffman said the results were an important step in understanding the repercussions of radionuclides in Australia.
Next, researchers will evaluate the effects of such high radiation on the environment.
"It's kind of like walking before you can run," she said.
"Now that we have these numbers or values in hand, then we can later do those assessments in terms of … how much radiation a person, or perhaps most important with sediment considering it's under water … the animals, the fish, and the plants are exposed to."
For Cam McGurk, his appreciation for the "boating and fishermen's playground" reels back to 1998, when a special permit was needed to travel there.
He mused that the legend of atomic testing had likely shielded the islands from over-tourism, but supported further monitoring.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
3 hours ago
- News.com.au
NSW Liberal leader Mark Speakman says AI Minister would free teachers, nurses from ‘mundane tasks'
NSW Opposition Leader Mark Speakman says an Australia-first Minister for Artificial Intelligence would free teachers and nurses from 'mundane tasks', as the Coalition twists the knife on Labor over AI and housing. The Liberal leader made his pitch for an AI-driven solution to NSW's productivity crisis during a scathing budget reply speech on Thursday. Mr Speakman said a Coalition government would establish a Minister for AI and an AI action plan, as well as low-interest 'AI for Biz' loans for small and medium-sized business looking to introduce 'responsible AI'. In an exclusive interview, Mr Speakman shed new light on the potential remit of the Australian-first minister, which he said would engage with the private sector to ensure the public service was 'using AI as much as possible'. 'It can relieve our teachers, our nurses, a whole lot of public sector workers of mundane tasks, improve productivity, and drive every tax dollar further,' he said. 'At a time when we've all got a cost-of-living crisis, we want to see our taxpayer dollars go as far as possible, and we think that (AI) is a great way to drive it. 'Every technological change has increased living standards and I want Australia and NSW to be leaders of that, not followers.' If established, the new ministry would be an Australian-first and joins only a small handful of countries that have similar AI-specific government roles, including Canada, France, the United Arab Emirates, and Taiwan. Asked about fears AI might take jobs, Mr Speakman recalled the anti-technology 19th century Luddites, who 'threw their shoes in machines'. 'Every time you've had major technological change in the history of humankind that's been a fear,' Mr Speakman said of job losses. 'Across the economy, it'll be impacted (by AI) but I think you'll end up with more jobs, not fewer. 'There'll be very different jobs and more productive jobs and ultimately higher living standards.' Mr Speakman said that there may be 'different jobs' with AI, but that it 'doesn't take them away', and that the AI Minister would be responsible for re-skilling. While increasingly commonplace, AI remains a controversial topic in many workplaces. Public Service Association Assistant General Secretary Troy Wright said AI had 'thus far failed because it lacks the empathy of a human' in public facing role trials. 'We need to think twice before we set AI loose in the public sector because we store a lot of the public's confidential and personal information and keeping that secure must be our number one priority,' he said. 'We do agree about the need to closely monitor the use of AI in the public sector and will be consulting with the Minns Government on their approach so the public can rest assured both that their personal information is safe and they have timely access to the frontline services they're entitled to.' Housing the 'biggest issue in town' It comes as the Coalition twists the knife on Labor following its third budget under Treasurer Daniel Mookhey, and less than two years out from the next state election. Mr Speakman has accused Labor of not doing enough on cost of living, and has pledged to reinstate the Full Active Kids Program, establish a 'fairer' payroll tax scheme for small businesses, as well as preventive health hubs, expanded telehealth, and prioritising emergency care. But, it was housing that Mr Speakman was the 'biggest issue in town'. He claimed the budget showed Labor would fall 137,000 homes short of the National Housing Accord target. 'Ultimately, the price of anything, whether you're a rent or buy, is a product of supply and demand,' he said. 'But, the government is failing to get the number of home completions we need to ramp up supply to make our homes affordable.' Mr Speakman called for government to address the 'biggest obstacles', namely taxes and charges on developers, as well as critical adjoining infrastructure. He said a Coalition government would reintroduce the First Homebuyers Choice Program and exempting stamp duty for eligible older Australians looking to downsize. It comes as NSW Premier Chris Minns remains mum on the state government's so-called 'Plan B' for housing close to the city after the failure of the Rosehill purchase. Members of the Australian Turf Club last month voted to reject a $5bn deal for the historic racecourse, which would have paved the way for 25,000 new homes. Asked about whether the Coalition had its own 'Plan B', Mr Speakman said to 'wait and see' and highlighted the party's own 2022 plan for Rosehill. The Labor government announced a range of housing measures in the 2025-26 budget, including that the state will go guarantor for developers on some 5000 homes.


West Australian
6 hours ago
- West Australian
New dawn for NeuroScientific with stem cell acquisition
Stem cell therapies have long promised to press the body's reset button - potentially reversing injuries and damage from disease, regenerating tissue and reshaping modern medicine. For ASX-listed NeuroScientific Biopharmaceuticals, that promise starts now thanks to its $5.1 million acquisition of unlisted Perth-based stem cell therapy company Isopogen. The deal will hand NeuroScientific the keys to Isopogen's patented 'StemSmart' technology, which innovatively prepares a specific type of stem cell, mesenchymal stem cells (MSC), for use as an intravenous infusion. MSC are universal donor cells, meaning that there is no need for matching between a donor and recipient. The are effectively an 'off-the shelf' cell therapy. Over the past 20 years, haematology medical scientist Dr Marian Sturm, NeuroScientific's incoming chief scientific officer, pioneered the development of MSCs in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. The cells have so far been used in many patients, including as a last-line treatment for critically ill patients suffering severe immune complications from bone marrow transplantation and in kidney and lung transplant rejection, through early phase clinical trials and studies and on compassionate grounds, with promising results. The MSC technology has also been employed to treat patients with severe Crohn's disease, an inflammatory autoimmune condition that affects the gut. The disease can develop into very difficult-to-manage and treat forms, including refractory Crohn's, in which patients experience persistent uncontrolled flare-ups, and fistulising Crohn's, in which patients develop an open wound from a gut flare-up out to the skin. In a phase two trial targeting refractory Crohn's disease, a condition that no longer responds to standard treatments, of 18 patients treated with StemSmart MSC, 78 per cent of patients experienced clinical improvement and 44 per cent achieved full remission. That level of efficacy is considered impressive in the MSC field, particularly for refractory Crohn's. With the global market for refractory Crohn's treatment alone estimated to be worth about US$7.5 billion, it's no wonder StemSmart's new owner quickly hailed the system as a potential game-changer. StemSmart technology offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital (RPH) and manufactured using RPH's processes. Notably, the manufacturing methodology can yield more than 200 cryopreserved clinical doses from just 10 millilitres of precious donated bone marrow, giving it both clinical flexibility and manufacturing scale. Based on the early results in Crohn's disease and in other conditions, Sturm now sees hope in employing MSCs to treat other autoimmune and inflammatory diseases, possibly including lupus, multiple sclerosis and rheumatoid arthritis. As the cells can grow into skin, bone, fat and other tissue cells, they also offer potential applications for tissue repair, such as bone repair for skull or long bone injuries, for example. The clinical development of MSC stretches back to 2002, when a Swedish paediatric haematologist used MSCs for the first time to treat a child gravely ill with complications from the treatment of leukaemia. The cells were isolated and grown in the doctor's laboratory from bone marrow donated by the child's mother. The child's clinical response to the cells was striking. No doubt, the successful experimental treatment would have caught the attention of immunology and haematology researchers and clinicians worldwide, including Sturm, an expert in blood, cell and tissue transplant manufacturing for clinical applications, who was the then-director of RPH's cutting-edge Cell and Tissue Therapy facility. At the time, Sturm was particularly focused on delivering MSCs as safely as possible into healthcare areas of unmet need. She began experimenting with ways to process the cells into a safe infusion that could be used to treat diseases and transplant complications where there were few or no existing clinical options. In 2007, Dr Sturm was approached by her clinical colleagues, who wanted to use the MSC product on compassionate grounds to treat a critically ill man with complications of bone marrow transplant to treat blood cancer. At the time, about 60 per cent of bone marrow transplant patients, who received donor marrow, developed a serious complication, known as graft-versus-host disease (GVHD), where the new blood system created by the bone marrow transplant rejects the recipient's body. It usually presents with symptoms that affect the gut, skin and liver, and is treated with steroids. With recent advancements in transplant practices, the incidence of acute GVHD has fallen to now occurring in about 25-30 per cent of cases. However, these medicines fail in about 30 per cent of acute GVHD cases – and most of this group die. After receiving MSC treatment, the man quickly recovered, spurring Sturm to keep working to develop a scalable, commercial-grade MSC product and patenting the manufacturing process. After an agreement was reached between Isopogen and the State Government's East Metropolitan Health Service (EMHS) giving Isopogen control of the MSC technology, NeuroScientific struck a deal with Isopogen to progress StemSmart. The all-scrip acquisition sees Isopogen shareholders receive 85.7 million NeuroScientific shares and 57.1 million performance shares tied to future clinical and commercial milestones. The market welcomed the move, with NeuroScientific's share price surging 97 per cent on the day of the announcement. A $3.5 million capital raise led by Perth corporate advisor Westar Capital, after existing funds, creates a war chest of about $7.5 million. This will support further development, including for a special access program or bigger phase 2/3 trials for patients with refractory and fistulising Crohn's, and will enable regulatory engagement with Australia's Therapeutic Goods Administration with a long-term goal of partial or full registration for StemSmart MSC, first up as a Crohn's treatment. The company is also eyeing the United States, where inflammatory bowel disease is forecast to grow into a lucrative US$13.8 billion market by 2026. About 30 per cent of Crohn's patients fail to respond to current gold-standard treatments, such as biologics, making them prime candidates for a new approach, such as StemSmart. The takeover signals a bold pivot for NeuroScientific, which previously focused on peptide-based drugs for neurodegenerative diseases such as Alzheimer's. Those drugs showed promise, but the timelines to market were long. By contrast, StemSmart's progress and results over decades of development position the product closer to near-term commercialisation, helped along by NeuroScientific's healthy bank balance. Nor will NeuroScientific be walking away from its roots completely. Two current directors will remain on the company's revamped board, and management will explore crossover applications for StemSmart, particularly to tackle the neuroinflammation that is a hallmark of inflammatory diseases such as Alzheimer's. That convergence could open a dual-front therapeutic pipeline, leveraging both peptide and cellular approaches. While competition in the stem cell space is fierce, the upside is enormous. Importantly, the US Food and Drug Administration (FDA) recently approved the first mesenchymal stromal cell therapy by ASX-listed, regenerative medicine company Mesoblast. While MSC products have been approved in other jurisdictions, the FDA approval of an allogeneic, bone marrow-derived MSC product for paediatric, steroid-refractory, acute graft-versus-host disease is momentous. According to NeuroScientific, StemSmart is differentiated by its purity, potency and consistency. In preclinical and early human data, the platform has shown enhanced potency over conventional MSCs. The recent regulatory FDA approval of MSC also tilt the momentum in StemSmart's favour, suggesting regulators are warming to well-characterised stem cell platforms with rigorous clinical data. Is your ASX-listed company doing something interesting? Contact:

The Age
6 hours ago
- The Age
New dawn for NeuroScientific with stem cell acquisition
Stem cell therapies have long promised to press the body's reset button - potentially reversing injuries and damage from disease, regenerating tissue and reshaping modern medicine. For ASX-listed NeuroScientific Biopharmaceuticals, that promise starts now thanks to its $5.1 million acquisition of unlisted Perth-based stem cell therapy company Isopogen. The deal will hand NeuroScientific the keys to Isopogen's patented 'StemSmart' technology, which innovatively prepares a specific type of stem cell, mesenchymal stem cells (MSC), for use as an intravenous infusion. MSC are universal donor cells, meaning that there is no need for matching between a donor and recipient. They are effectively an 'off-the shelf' cell therapy. Over the past 20 years, haematology medical scientist Dr Marian Sturm, NeuroScientific's incoming chief scientific officer, pioneered the development of MSCs in her former role as facility director of Royal Perth Hospital's Cell and Tissue Therapies centre. The cells have so far been used in many patients, including as a last-line treatment for critically ill patients suffering severe immune complications from bone marrow transplantation and in kidney and lung transplant rejection, through early phase clinical trials and studies and on compassionate grounds, with promising results. The MSC technology has also been employed to treat patients with severe Crohn's disease, an inflammatory autoimmune condition that affects the gut. The disease can develop into very difficult-to-manage and treat forms, including refractory Crohn's, in which patients experience persistent uncontrolled flare-ups, and fistulising Crohn's, in which patients develop an open wound from a gut flare-up out to the skin. 'NSB's acquisition of Isopogen will allow our StemSmart technology to be progressed for the benefit of vulnerable patients with limited treatment options.' NeuroScientific Biopharmaceuticals incoming chairman Robert McKenzie In a phase two trial targeting refractory Crohn's disease, a condition that no longer responds to standard treatments, of 18 patients treated with StemSmart MSC, 78 per cent of patients experienced clinical improvement and 44 per cent achieved full remission. That level of efficacy is considered impressive in the MSC field, particularly for refractory Crohn's. With the global market for refractory Crohn's treatment alone estimated to be worth about US$7.5 billion, it's no wonder StemSmart's new owner quickly hailed the system as a potential game-changer. StemSmart technology offers a step up from traditional MSC manufacturing in that the cells are grown in a special media, becoming activated in the process. The platform technology was developed at Royal Perth Hospital (RPH) and manufactured using RPH's processes.